Modulation of cellular proliferation and production of prostate-specific antigen and matrix adhesion molecules in human prostate carcinoma cells by polypeptide growth factors: Comparative analyses of MDA PCa2a with established cell lines

International Journal of Oncology

Volumn 12, Issue 3, 1998, Pages 589-595

  Rajagopal, Sriram ^a   Navone, Nora M ^a   Troncoso, Patricia ^a   Fritsche, Herbert A ^a   Chakrabarty, Subhas ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Growth factors; Matrix adhesion molecules; Prostate cancer

Indexed keywords

ANDROGEN; CELL ADHESION MOLECULE; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; GROWTH FACTOR; LAMININ; PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA;

ADENOCARCINOMA; CELL DIVISION; EPIDERMAL GROWTH FACTOR; FIBRONECTINS; GROWTH SUBSTANCES; HUMANS; LAMININ; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0031908548     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.3.589     Document Type: Review

References (62)

1. Cross M and Dexter TM: Growth factors in development, transformation, and tumorigenesis. Cell 64: 271-280, 1991.
2. Kerbel RS: Growth factors as mediators of malignant tumor progression. Cancer Metastasis Rev 12: 215-217, 1993.
3. Hay ED: Extracellular matrix. J Cell Biol 91: 205s-223s, 1981.
4. Edelman GM: Cell adhesion molecules. Science 219: 450-457, 1983.
5. Ruoslahti E and Pierschbacher MD: New perspectives in cell adhesion: RGD and integrins. Science 238: 491-497, 1987.
6. Lin CQ and Bissel MJ: Multi-faceted regulation of cell differentiation by extracellular matrix. FASEB J 7: 737-741, 1993.
7. Jones PL, Schmidhauser C and Bissell MJ: Regulation of gene expression and cell function by extracellular matrix. Crit Rev Eukaryot Gene Expr 3: 137-154, 1993.
8. Roskelley CD, Desprez YP and Bissell MJ: Extracellar matrix-dependent tissue-specific gene expression in mammary epithelial cells required both physical and biochemical signal transduction. Proc Natl Acad Sci USA 91: 12378-12382, 1994.
9. Clark EA and Brugge SS: Integrins and signal transduction pathway: the road taken. Science 268: 233-238, 1995.
10. Kramer RH, Enenstein J, Ramos DM, Vu MP and Cheng YF: The role of integrin receptors in tumor cell adhesion to the microvasculature. In: Microcirculation in Cancer Metastasis. Buchanan MR and Weis L (eds). CRC Press, Boca Raton, pp145-167, 1991.
11. Juliano RL: Membrane receptors for extracellular matrix macromolecules: relationship to cell adhesion and tumor metastasis. Biochim Biophys Acta 907: 261-278, 1987.
12. Juliano RL: Signal transduction by integrins and its role in the regulation of tumor growth. Cancer Metastasis Rev 13: 25-30, 1994.
13. Moses HL, Yang EY and Pietenpol JA: TGFβ stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63: 245-247, 1990.
14. Barnard JA, Lyons RM and Moses HL: The cell biology of transforming growth factor β. Biochim Biophys Acta 1032: 79-87, 1990.
15. Chakrabarty S, Fan D and Varani J: Regulation of differentiation and cellular proliferation in human colon carcinoma cells by transforming growth factor beta 1 and beta 2. Int J Cancer 46: 493-499, 1990.
16. Wu S, Thcodorescu D, Kerbel RS, Willson JKV, Mulder KM, Humphrey LE and Brattain MG: TGF-β1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol 116: 187-196, 1992.
17. Wu S, Sun L-S, Willson JKV, Humphrey LE, Kerbel RS and Brattain MG: Repression of autocrine transforming growth factor B1 and β2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties. Cell Growth Differ 4: 115-123, 1995.
18. Sun L-H, Wu SP, Coleman K, Fields KC, Humphery LE and Brattain GM: Autocrine transforming growth factor β1 and β2 expression is increased by cell crowding and quiescence in colon carcinoma cells. Exp Cell Res 214: 215-224, 1994.
19. Steiner MS: Transforming growth factor-β and prostate cancer. World J Urol 13: 329-336, 1995.
20. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L-Z, Lutterbaugh J, Fam RS, Zborowska EW, Volgestein B, Brattain MG and Willson JKV: Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338, 1995.
21. Chakrabarty S, Jan Y, Brattain MG, Tobon A and Varani J: Diverse cellular responses elicited from human colon carcinoma cells by transforming growth factor-β. Cancer Res 49: 2112-2117, 1989.
22. Chakrabarty S: Regulation of human colon carcinoma cell adhesion to extracellular matrix by transforming growth factor-β1. Int J Cancer 50: 968-973, 1992.
23. Huang S and Chakrabarty S: Regulation of fibronectin and laminin receptor expression, fibronectin and laminin secretion in human colon cancer cells by transforming growth factorβ1. Int J Cancer 57: 742-746, 1994.
24. Huang S and Chakrabarty S: Expression of antisense fibronectin RNA in human colon carcinoma cells disrupts the regulation of carcinoembryonic antigen by transforming growth factor β1. J Biol Chem 269: 28764-28768, 1994.
25. Huang S, Trujillo JM and Chakrabarty S: Proliferation of human colon cancer cells: role of epidermal growth factor and transforming growth factor α. Int J Cancer 52: 978-986, 1992.
26. Chakrabarty S, Rajagopal S and Huang S: Expression of antisense epidermal growth factor receptor RNA downmodulated the malignant behavior of human colon cancer cells. Clin Exp Metastasis 13: 191-195, 1995.
27. Rajagopal S, Huang S, Moskal TL, Lee B-N, El-Naggar EL and Chakrabarty S: Epidermal growth factor expression in human colon and colon carcinomas: antisense epidermal growth factor receptor RNA downregulates the proliferation of human colon cancer cells. Int J Cancer 62: 661-667, 1995.
28. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucanan DC and Fidler JI: Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1: 19-31, 1995.
29. Myers R, Kudlow JE and Grizzle WE: Expression of transforming growth factor-alpha, epidermal growth factor and epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia. Mod Path 6: 733-737, 1993.
30. Ching KC, Ramsey E, Pettigrew N, Cunha DR, Jason M and Dodd JG: Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Mol Cell Biochem 126: 151-158, 1993.
31. Limonta P, Moretti RM, Dondi D, Marelli MM and Motta M: Androgen-dependent prostatic tumors: biosynthesis and possible actions of LHRH. J Steroid Biochem Mol Biol 49: 347-350, 1994.
32. Liu XH, Wiley HS and Meikle AW: Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. J Clin Endocrinol Metab 77: 1472-1478, 1993.
33. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapan J, Hittmair A, Bartsch G and Klocker H: Androgen receptor activation in prostate tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478, 1994.
34. Fong CJ, Sherwood ER, Mendelsohn J, Lee C and Kozlowski JM: Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. Cancer Res 52: 5887-5892, 1992.
35. Penttinen PR, Kobayashi S and Bornstcin P: Transforming growth factor β increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc Natl Acad Sci USA 85: 1105-1108, 1988.
36. Laiho M and Keski-oja J: Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res 49: 2533-2553, 1989.
37. Guo Y, Pili R and Passaniti A: Regulation of prostate-specific antigen gene expression in LNCap human prostatic carcinoma cells by growth, dihydrotestosterone, and extracellular matrix. Prostate 24: 1-10, 1994.
38. Chung WKL: The role of stromal-epithelial interation in normal and malignant growth. Cancer Surv 23: 33-42, 1995.
39. Sonmez H, Suer S, Karaaslan H, Baloglu H and Kokoglu E: Tissue fibronectin levels of human prostatic cancer, as a-tumor marker. Cancer Biochem Biophys 15: 107-110, 1995.
40. Suer S, Sommez H, Karaaslan H, Baloglu H and Kokoglu E: Tissue sialic acid and fibronectin levels in human prostatic cancer. Cancer Lett 99: 135-137, 1996.
41. Navone MN, Olive M, Ozen M, Davis R, Troncoso P, Tu S-M, Johnston D, Pollack A, Pathak S, Eschenbach ACV and Logothetis C: Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res (In press).
42. Carmichael J, Degraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
43. Fan D, Chakrabarty S, Deid C, Bell CW, Schackert H, Marikawa K and Fidler IJ: Clonal stimulation or inhibition of human colon carcinomas and human renal carcinomas mediated by transforming growth factor-β1. Cancer Commun I: 117-125, 1989.
44. Heo DS, Park J-G, Hata K, Day R, Herbermann RB and Whiteside TL: Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res 50: 3681-3690, 1990.
45. Kim YI, Zelner JD, Sensibar AJ, Ahn H-J, Park L, Kim J-H and Lee C: Modulation of sensitivity to transforming growth factor-β1 (TGF-β1) and the level of type II TGF-β receptor in LNCap cells by dihydrotestosterone. Exp Cell Res 222: 103-110, 1996.
46. Wilding G, Zugmeier G, Knabbe C, Flanders K and Gelmann E: Differential effect of transforming growth factor β on human prostate cancer cell in vitro. Mol Cell Endocrinol 62: 79-87, 1989.
47. Hofer RD, Sherwood RE, Bromberg DW, Mendelsohn J and Lee C: Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor α. Cancer Res 51: 2780-2785, 1991.
48. Connolly MJ and Rose PD: Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate 19: 173-180, 1991.
49. MacDonald A and Habib FK: Divergent responses to epidermal growth in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer 65: 177-182, 1992.
50. Sokoloff MH, Tso CL, Kaboo R, Taneja S, Pang S, Dekernion JB and Belldegrum AS: In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer 77: 1862-1872, 1996.
51. Montgomery TB, Young Y-FC, Bilhartz LD, Andrews EP, Prescott LJ, Thompson FN and Tindall JD: Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in human prostate adenocarcinoma cell line, LNCap. Prostate 21: 63-73, 1992.
52. Henttu P and Vihko P: Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCap. Cancer Res 53: 1051-1058, 1993.
53. Decker JS: Epidermal growth factor and transforming growth factor-alpha induce differential processing of the epidermal growth factor receptor. Biochem Biophys Res Commun 166: 615-621, 1990.
54. Ebner R and Derynck R: Epidermal growth factor and transforming growth factor-α: differential intracellular routing and processing of ligand-receptor complexes. Cell Regulation 2: 599-612, 1991.
55. Filhol O, Chambaz EM, Gill NG and Cochet C: Epidermal growth factor stimulates a protein tyrosine kinase which is separate from epidermal growth factor receptor. J Biol Chem 25: 26978-26982, 1993.
56. Varani J and Chakrabarty S: Modulation of fibronectin synthesis and fibronectin binding during transformation and differentiation of mouse AKR fibroblasts. J Cell Physiol 143: 445-454, 1990.
57. Huang S, Varani J and Chakrabarty S: Control of AKR fibroblast phenotype by fibronectin: regulation of cell-surface fibronectin binding receptor by fibronectin. J Cell Physiol 161: 470-482, 1994.
58. Akamatsu H, Ichihara-Tanaka K, Ozono K, Kamiike W, Matsuda H and Sekiguchi K: Suppression of transformed phenotypes of human fibrosarcoma cells by overexpression of recombinant fibronectin. Cancer Res 56: 4541-4546, 1996.
59. Steel MD and Harris H: The effect of antisense RNA to fibronectin on the malignancy of hybrids between melanoma cells and normal fibroblasts. J Cell Sci 93: 515-524, 1989.
60. Varani J, Schuger L, Fligiel SEG, Inman DR and Chakrabarty S: Production of fibronectin by human tumor cells and interaction with exogenous fibronectin: comparison of cell lines obtained from adenocarcinomas and squamous carcinomas of the upper aerodigestive tract. Int J Cancer 47: 421-425, 1991.
61. Takei H, Iino Y, Horiguchi J and Yokoe T: Immunohistochemical fibronectin staining pattern and prognosis in invasive breast carcinoma. Oncology 52: 106-111, 1995.
62. Franzen P, Ichijo H and Miyazono K: Different signals mediate transforming growth factor-β1-induccd growth inhibition and extracellular matrix production in prostatic carcinoma cells. Exp Cell Res 207: 1-7, 1993.